REPL
Companies
NASDAQ
Replimune Group Inc.
Health Care
$9.49
-$2.62 (-21.64%)
Price Chart
Overview
About REPL
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Market Cap
$485.2M
Volume
11.7M
Avg. Volume
10.5M
P/E Ratio
-3.4163566
Dividend Yield
0.00%
Employees
287.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.60
High Correlation
Volatility
High (0.77)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, REPL shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$485.2M
Volume11.7M
P/E Ratio-3.42
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 12, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025